Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Contract Win

19 Jan 2005 07:00

Embargoed Release: 07:00hrs Wednesday 19 January 2005 SOPHEON PLC (`Sopheon') Atrium Medical Center Selects Sopheon's Accolade Solution to Manage Clinical Trials and Innovation Projects Software Will Support Compliance with New European-Union Clinical Trial Regulations and Help Ensure Projects Are Executed Efficiently and On Time Sopheon, the international provider of solutions that improve the return frominnovation and product development, announces that Atrium Medical Center, oneof the largest general hospitals in the Netherlands, is deploying Sopheon'sAccolade solution to support implementation of a structured process forcomprehensive management of clinical trials. Use of the software is expected tohelp Atrium enhance management of trials activity and ensure compliance withthe latest European Union (EU) clinical research regulations. Accolade willalso be used by the hospital to manage innovation projects, including majorcapital investment initiatives."Pharmaceutical companies judge our clinical-trial work by the quality of theresults and the speed and cost-effectiveness with which those results aredelivered," said Dr. Graham Ramsay of Atrium's board. "Patients depend upon ourability to effect the right kinds of innovation and make the right capitalinvestments to ensure that they receive the best available care. Sopheon'ssoftware will integrate our processes for managing clinical trials andinnovation projects, making those processes more stable, predictable andefficient."The hospital is deploying Accolade at its facilities in Heerlen, Kerkrade andBrunssum. Atrium conducts approximately 70 clinical trials per year for leadingpharmaceutical companies. It is anticipated that use of the software system,which will eventually handle as many as 240 trials at one time, will increaseclinical-trials revenue by enabling faster trial preparation and execution,higher quality results and improved service to clients. Sopheon also workedclosely with Atrium to configure Accolade to fit a new, jointly-developedprocess incorporating elements of the Six Sigma manufacturing methodology thatwill be applied to management of innovation initiatives.Accolade will replace the manual, paper-based process structure that Atriumpreviously used to manage clinical trials with a reliable, easy-to-useWeb-based framework for everything from tracking schedules and budgets toassessing and allocating resources, conducting financial analyses and examiningtrial results. The system provides hospital executives, managers, clinicaltrial coordinators, doctors and researchers with the information supportrequired for tactical, day-to-day management activity as well as for strategic,longer-term business decision-making. Atrium plans to extend access to thesystem to pharmaceutical clients interested in checking on the status of trialprojects involving their products.Sopheon's CEO Andy Michuda said:"Clinical trial management is a critical step in the cycle that movespharmaceutical products from conception and development to safe adoption in themarketplace. It's estimated that, in the United States alone, approximately80,000 clinical trials are being conducted at any one time. The scale ofopportunity associated with effecting improvements in this area is great.Accolade's capacity to reduce the expense and inefficiency of the clinicaltrial process has led to its adoption by some of the leading clinical hospitalsin the world. Atrium is one such leader, and a prime example of how forwardthinking healthcare providers are harnessing technology to benefit stakeholdersthroughout the value chain."For further information contact:Barry Mence, Chairman Sopheon plc Tel : + 44 (0) 1483 685 735 Arif Karimjee, CFO Adam Reynolds Hansard Communications Tel : + 44 (0) 207 245 1100 Andrew Tan + 44 (0) 7957 203 685 Barbara Jansen Citigate First Financial Tel : + 31 (0) 205 754 010About Atrium Medical CenterWith 3600 employees and 1230 beds, Atrium Medical Center (Atrium) is one of thelargest employers in the south of the Netherlands. In 2004 Atrium celebratedits 100-year anniversary. It has a national reputation for hospital innovation,and has recently participated in experimental studies on reducing patientwait-lists, increasing care-delivery production, implementing new budgetarysystems and improving patient safety. In 2003, supported by a ¢â€š¬187 millionbudget, Atrium registered 28,000 clinical admissions, 24,000 day admissions and432,000 patient visits to its policlinics. Atrium's focus on patients,professionalism, and continuity and effectiveness of treatment ensures that thequality of care it provides remains on the highest levels.About SopheonSopheon (LSE: SPE) is an international provider of software and services. TheSopheon Accolade product development system automates gate- or phase-basedproduct development processes and provides strategic decision support thatallows companies to improve innovation, cut product development spending wasteand shorten time-to-market. Sopheon's Monitor software operates as a "readingrobot" that automatically reviews, filters, analyzes and pushes relevantcontent to healthcare and engineering professionals to enable effectivecompliance with protocols, standards and regulations. Sopheon is listed on theAIM Market of the London Stock Exchange and on the Euronext in the Netherlands.For more information, please visit www.sopheon.com.END
Date   Source Headline
30th Jan 201810:27 amRNSIssue of Equity
29th Jan 20187:00 amRNSTrading Update
4th Jan 20182:05 pmRNSSecond Price Monitoring Extn
4th Jan 20182:00 pmRNSPrice Monitoring Extension
4th Jan 20187:00 amRNSTrading Update
22nd Dec 20171:01 pmRNSHolding(s) in Company
22nd Dec 201712:37 pmRNSConversion of Loan Stock
8th Dec 20177:00 amRNSAmendment to the Terms of Convertible Loan Stock
9th Nov 20177:00 amRNSCertis Europe Partners with Sopheon
19th Oct 20177:00 amRNSSopheon Funding Award
11th Oct 201710:44 amRNSDirector/PDMR Shareholding
2nd Oct 20177:00 amRNSIssue of Equity
26th Sep 20177:00 amRNSSopheon "Leader" in Strategic Portfolio Management
5th Sep 20177:00 amRNSSopheon's Accolade Software beyond innovation
24th Aug 20177:00 amRNSHalf Yearly Report
21st Jul 201710:32 amRNSDirector Shareholdings
6th Jul 20177:00 amRNSAccolade Release 11.2
29th Jun 20177:00 amRNSNew Approach to Product Development with Accolade
13th Jun 201712:04 pmRNSDirector Shareholdings
8th Jun 201712:09 pmRNSResult of AGM
8th Jun 20177:00 amRNSAGM Statement
26th May 20174:33 pmRNSIssue of Equity
26th Apr 20173:50 pmRNSIssue of Equity
12th Apr 201712:01 pmRNSIssue of Equity
7th Apr 20171:37 pmRNSDirector Shareholdings
31st Mar 20177:00 amRNSDirector Shareholdings
31st Mar 20177:00 amRNSIssue of Equity
23rd Mar 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSAccolade Release 11.1
16th Feb 20177:00 amRNSGrant of Options / PDMR dealing
30th Jan 20177:00 amRNSTrading Update
21st Nov 201611:50 amRNSIssue of Equity
3rd Nov 20168:00 amRNSAccolade Release 11.0
29th Sep 201612:41 pmRNSIssue of Equity
22nd Sep 20169:09 amRNSIssue of Equity
15th Sep 20163:09 pmRNSIssue of Equity
25th Aug 20167:00 amRNSHalf Yearly Report
28th Jul 20165:01 pmRNSHolding(s) in Company
26th Jul 201610:49 amRNSHolding(s) in Company
12th Jul 201610:48 amRNSHolding(s) in Company
29th Jun 20165:32 pmRNSDirector Dealing
16th Jun 20164:22 pmRNSDirector Dealing
14th Jun 20164:18 pmRNSDirector Dealing
10th Jun 20162:13 pmRNSDirector Dealing
9th Jun 201611:37 amRNSResult of AGM
9th Jun 20167:00 amRNSAGM Statement
31st May 20163:09 pmRNSIssue of Equity
5th May 20161:25 pmRNSHolding(s) in Company
4th May 20167:00 amRNSAccolade Release 10.3
3rd May 20161:27 pmRNSDirector Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.